Loading AI tools
Norepinephrine reuptake inhibitor From Wikipedia, the free encyclopedia
Ampreloxetine (INN , USAN ; developmental code name TD-9855) is a selective norepinephrine reuptake inhibitor (NRI) which is under development for the treatment of symptomatic neurogenic orthostatic hypotension (NOH).[2][3][4]
Clinical data | |
---|---|
Other names | TD-9855 |
Drug class | Norepinephrine reuptake inhibitor; Serotonin–norepinephrine reuptake inhibitor |
Pharmacokinetic data | |
Elimination half-life | 30–40 hours[1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C18H18F3NO |
Molar mass | 321.343 g·mol−1 |
3D model (JSmol) | |
| |
|
It shows high affinity for both the norepinephrine transporter (NET) and the serotonin transporter (SERT), with 4-fold selectivity for the NET over the SERT, and is thought to act as a dual serotonin–norepinephrine reuptake inhibitor (SNRI) at higher doses.[4][1]
As of November 2023, ampreloxetine is in phase 3 clinical trials for NOH.[2] The drug was also under development for the treatment of attention deficit hyperactivity disorder (ADHD) and fibromyalgia, but development for these uses was discontinued.[2][5]
Seamless Wikipedia browsing. On steroids.
Every time you click a link to Wikipedia, Wiktionary or Wikiquote in your browser's search results, it will show the modern Wikiwand interface.
Wikiwand extension is a five stars, simple, with minimum permission required to keep your browsing private, safe and transparent.